<DOC>
	<DOCNO>NCT02263066</DOCNO>
	<brief_summary>To assess describe real-life treatment choice rFⅧ contain regular prophylaxis/bleeding prevention treatment pediatric hemophilia patient China ( 2007-2013 )</brief_summary>
	<brief_title>Retrospective Study Chinese Pediatric Hemophilia A Patients With rFⅧ Contained Regular Prophylaxis</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male , 2＜18 year Hemophilia A , base document prior test and/or screen laboratory Patients receive regular prophylaxis/bleeding prevention treatment , totally/partially rFⅧ . Regular prophylaxis/bleeding prevention treatment define proportion week ( ≥2 infusion/week ) total treatment weeks≥80 % [ 10 ] , total duration ≥12 week . During regular prophylaxis period , consecutive 4 week ＜2 infusion/week , begin day 4 week defined end regular prophylaxis . Available patient medical data record Written inform consent parent/legal representative . Consent seek subject appropriate Patients measurable inhibitor activity baseline history FVIII inhibitor antibody formation ( ≥0.6BU Bethesda assay two different time point , documentation must available ) Any individual another bleed disease different hemophilia A ( e.g , von Willebrand disease , hemophilia B )</criteria>
	<gender>Male</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>